Asia
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
Two months after he was stepped down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang has been arrested for smuggling genetic resources from the People’s Republic of China.
While many microbiome therapies rely on adding bacteria, like probiotics, Israel-based BiomX takes a somewhat unique approach of removing harmful bacteria.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
The fourth Amendment of the China Patent Law has been deliberated and was passed on October 17, 2020. It will come into force on June 1, 2021. For the medical industry, China’s proposed patent linkage system can be more favorable to generic drug companies than the U.S. system.
Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells.
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES